Departement
Klinische Forschung
Achtung: Diese Seite kann nur von Administratoren besucht werden, da Sie nicht freigeschalten wurde.
Zurück
Publications Rentsch Cyrill A.

Critical Evaluation of Transcripts and Long Noncoding RNA Expression Levels in Prostate Cancer Following Radical Prostatectomy.

Ruiz C; Alborelli I; Manzo M; Calgua B; Keller EB; Vuaroqueaux V; Quagliata L; Rentsch CA; Spagnoli GC; Diener PA; Bubendorf L; Morant R; former members of the Urology Team in St. Gallen; Eppenberger-Castori S. Pathobiology. 2023.

Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19).

Petrausch U; Spahn M; Schneider M; Hayoz S; Rentsch CA; Rothschild S; Omlin A; Cathomas R. BMJ Open. 2023.

A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.

Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S. European Urology Oncology. 2022.

High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores.

Vlajnic T; Brunner P; Eppenberger-Castori S; Rentsch CA; Zellweger T; Bubendorf L. Pathobiology. 2022.

Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies.

Wetterauer C; Federer-Gsponer JR; Leboutte FDJP; Mona R; Ebbing J; Rentsch CA; Manka L; Seifert HH; Wyler S; Recker F; Kwiatkowski M. Urologia internationalis. 2022.

Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicenter, Phase 2 Study.

Rentsch CA; Hayoz S; Cathomas RL. European Urology. 2022.

Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy.

Bacon JVW; Müller DC; Ritch E; Annala M; Dugas SG; Herberts C; Vandekerkhove G; Seifert H; Zellweger T; Black PC; Bubendorf L; Wyatt AW; Rentsch CA. European Urology Oncology. 2022.

Enhancing disease awareness for tuberous sclerosis complex in patients with radiologic diagnosis of renal angiomyolipoma: an observational study.

Bausch K; Wetterauer C; Diethelm J; Ebbing J; Boll DT; Dill P; Rentsch CA; Seifert HH. BMC Nephrology. 2021.

Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer

Rentsch C.A.; Hayoz S.; Cathomas R.. The Lancet Oncology. 2021.

Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens.

Servant R; Garioni M; Vlajnic T; Blind M; Pueschel H; Müller DC; Zellweger T; Templeton AJ; Garofoli A; Maletti S; Piscuoglio S; Rubin MA; Seifert H; Rentsch CA; Bubendorf L; Le Magnen C. Journal of Pathology. 2021.

Autonomous Detection and Classification of PI-RADS Lesions in an MRI Screening Population Incorporating Multicenter-Labeled Deep Learning and Biparametric Imaging: Proof of Concept.

Winkel DJ; Wetterauer C; Matthias MO; Lou B; Shi B; Kamen A; Comaniciu D; Seifert HH; Rentsch CA; Boll DT. Diagnostics. 2020.

Patterns of stemness-associated markers in the development of castration-resistant prostate cancer.

Federer-Gsponer JR; Müller DC; Zellweger T; Eggimann M; Marston K; Ruiz C; Seifert HH; Rentsch CA; Bubendorf L; Le Magnen C. The Prostate. 2020.

Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy.

Rentsch CA; Bosshard P; Mayor G; Rieken M; Püschel H; Wirth G; Cathomas R; Parzmair GP; Grode L; Eisele B; Sharma H; Gupta M; Gairola S; Shaligram U; Goldenberger D; Spertini F; Audran R; Enoiu M; Berardi S; Hayoz S; Wicki A. Oncoimmunology. 2020.

The Importance of Standardised Recording of Intraoperative Adverse Events: Key Features of an Ideal Classification System.

Dell-Kuster S; Rentsch CA; Steiner LA; Rosenthal R. . 2020.

ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.

Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W. World Journal of Urology. 2019.

Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer.

Dugas SG; Müller DC; Le Magnen C; Federer-Gsponer J; Seifert HH; Ruiz C; Savic Prince S; Vlajnic T; Zellweger T; Mertz KD; Bacon JVW; Wyatt AW; Rentsch CA; Bubendorf L. Cancer cytopathology. 2019.

[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation].

Omlin A; Spahn M; Beyer J; Eberli D; Gillessen S; Jochum W; Kueng M; Nitzsche E; Rentsch CA; Roggero E; Schmid HP; Stenner F; Templeton AJ; Wild D; Wyler S; Zwahlen D; Cathomas R. Praxis. 2018.

Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.

Rentsch CA; Derré L; Dugas SG; Wetterauer C; Federer-Gsponer JR; Thalmann GN; Ingersoll MA. European Urology Focus. 2018.

Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance.

Federer-Gsponer JR; Quintavalle C; Müller DC; Dietsche T; Perrina V; Lorber T; Juskevicius D; Lenkiewicz E; Zellweger T; Gasser T; Barrett MT; Rentsch CA; Bubendorf L; Ruiz C. Journal of Pathology. 2018.

Donor-derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus.

Müller DC; Rämö M; Naegele K; Ribi S; Wetterauer C; Perrina V; Quagliata L; Vlajnic T; Ruiz C; Balitzki B; Grobholz R; Gosert R; Ajuh ET; Hirsch HH; Bubendorf L; Rentsch CA. Journal of Pathology. 2018.

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E. The Prostate. 2018.

Utility of cell based urinary tests in the follow-up after prostate cancer radiotherapy

Wetterauer, C; Rieken, M; Püschel, H; Ebbing, J; Papachristofilou, A; Gasser, T; Rentsch, CA. . 2018.

Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.

Mason MD; Clarke NW; James ND; Dearnaley DP; Spears MR; Ritchie AWS; Attard G; Cross W; Jones RJ; Parker CC; Russell JM; Thalmann GN; Schiavone F; Cassoly E; Matheson D; Millman R; Rentsch CA; Barber J; Gilson C; Ibrahim A; Logue J; Lydon A; Nikapota AD; O'Sullivan JM; Porfiri E; Protheroe A; Srihari NN; Tsang D; Wagstaff J; Wallace J; Walmsley C; Parmar MKB; Sydes MR; STAMPEDE Investigators. Journal of Clinical Oncology. 2017.

Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation?

Rentsch CA; Müller DC; Ruiz C; Bubendorf L. European Urology. 2017.

ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.

Chevalier MF; Trabanelli S; Racle J; Salomé B; Cesson V; Gharbi D; Bohner P; Domingos-Pereira S; Dartiguenave F; Fritschi AS; Speiser DE; Rentsch CA; Gfeller D; Jichlinski P; Nardelli-Haefliger D; Jandus C; Derré L. Journal of Clinical Investigation. 2017.

MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling

Offermann A.; Vlasic I.; Syring I.; Vogel W.; Ruiz C.; Zellweger T.; Rentsch C.A.; Hagedorn S.; Behrends J.; Nowak M.; Merseburger A.; Bubendorf L.; Kirfel J.; Duensing S.; Shaikhibrahim Z.; Perner S.. Oncotarget. 2017.

Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry.

Stenner F; Rothschild SI; Betticher D; Caspar C; Morant R; Popescu R; Rauch D; Huber U; Zenhäusern R; Rentsch C; Cathomas R. Clinical genitourinary cancer. 2017.

The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing.

Nieuwenhuizen NE; Kulkarni PS; Shaligram U; Cotton MF; Rentsch CA; Eisele B; Grode L; Kaufmann SHE. Frontiers in Immunology. 2017.

Celecoxib with or without zoledronic acid for hormone-naive prostate cancer: Survival results from STAMPEDE (NCT00268476)

James, Nicholas D.; Sydes, Matthew Robert; Clarke, Noel W.; Mason, Malcolm David; Dearnaley, David P.; Spears, Melissa Ruth; Ritchie, Alastair W. S.; Russell, J. Martin; Parker, Chris C.; Rentsch, Cyrill A.; Wallace, Jan; Barber, Jim; Lydon, Anna; Parmar, Mahesh K. B.. Journal of Clinical Oncology. 2016.

Dynamics of urinary calprotectin after renal ischaemia

Ebbing J.; Seibert F.S.; Pagonas N.; Bauer F.; Miller K.; Kempkensteffen C.; Gunzel K.; Bachmann A.; Seifert H.H.; Rentsch C.A.; Ardelt P.; Wetterauer C.; Amico P.; Babel N.; Westhoff T.H.. PLoS ONE. 2016.

Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer

Rentsch C.A.; Muller D.C.; Ruiz C.; Bubendorf L.. European Urology. 2016.

Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out Immunocompromised mice

Wetterauer C.; Vlajnic T.; Schuler J.; Gsponer J.R.; Thalmann G.N.; Cecchini M.; Schneider J.; Zellweger T.; Pueschel H.; Bachmann A.; Ruiz C.; Dirnhofer S.; Bubendorf L.; Rentsch C.A.. The Prostate. 2015.

Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the Doorstep.

Rentsch CA; Stenner F; Ruiz C; Bubendorf L. European Urology. 2015.

[Current developments in the medical treatment of advanced urothelial carcinoma of the bladder].

Schmid SC; Gschwend JE; Retz M; Arbeitsgemeinschaft Urologische Onkologie der Deutschen Krebsgesellschaft e. V. (AUO).. InFo Onkologie und Hämatologie. 2014.

Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.

Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN. European Urology. 2014.

Ceramic foam plates: a new tool for processing fresh radical prostatectomy specimens.

Vlajnic T; Oeggerli M; Rentsch C; Püschel H; Zellweger T; Thalmann GN; Ruiz C; Bubendorf L. Virchows Archiv. 2014.

Incidental prostate cancer prevalence at radical cystoprostatectomy--importance of the histopathological work-up.

Wetterauer C; Weibel M; Gsponer JR; Vlajnic T; Zellweger T; Bütikofer S; Müller G; Püschel H; Bachmann A; Gasser TC; Bubendorf L; Rentsch CA. Virchows Archiv. 2014.

Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer.

Ghadjar P; Oesch SL; Rentsch CA; Isaak B; Cihoric N; Manser P; Thalmann GN; Aebersold DM. Radiation Oncology. 2014.

MED12 overexpression is a frequent event in castration-resistant prostate cancer

Shaikhibrahim Z.; Offermann A.; Braun M.; Menon R.; Syring I.; Nowak M.; Halbach R.; Vogel W.; Ruiz C.; Zellweger T.; Rentsch C.A.; Svensson M.; Andren O.; Bubendorf L.; Biskup S.; Duensing S.; Kirfel J.; Perner S.. Endocrine-related cancer. 2014.

BCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model.

Rentsch CA; Biot C; Gsponer JR; Bachmann A; Albert ML; Breban R. PLoS ONE. 2013.

Characterization and clinical relevance of ALDHbright populations in prostate cancer.

Le Magnen C; Bubendorf L; Rentsch CA; Mengus C; Gsponer J; Zellweger T; Rieken M; Thalmann GN; Cecchini MG; Germann M; Bachmann A; Wyler S; Heberer M; Spagnoli GC. Clinical Cancer Research. 2013.

Dismembered and non-dismembered retroperitoneoscopic pyeloplasty for the treatment of ureteropelvic junction obstruction in children.

Subotic S; Weiss H; Wyler S; Rentsch CA; Rassweiler J; Bachmann A; Teber D. World Journal of Urology. 2013.

Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease.

Zellweger T; Stürm S; Rey S; Zlobec I; Gsponer JR; Rentsch CA; Terracciano LM; Bachmann A; Bubendorf L; Ruiz C. Endocrine-related cancer. 2013.

Potential consequences of low biopsy core number in selection of patients with prostate cancer for current active surveillance protocols.

Müller G; Bonkat G; Rieken M; Wyler SF; Bubendorf L; Püschel H; Gasser TC; Bachmann A; Rentsch CA. Urology. 2013.

Reply

Muller G.; Bachmann A.; Rentsch C.A.. Urology. 2013.

Deep clonal profiling of formalin fixed paraffin embedded clinical samples.

Holley T; Lenkiewicz E; Evers L; Tembe W; Ruiz C; Gsponer JR; Rentsch CA; Bubendorf L; Stapleton M; Amorese D; Legendre C; Cunliffe HE; McCullough AE; Pockaj B; Craig D; Carpten J; Von Hoff D; Iacobuzio-Donahue C; Barrett MT. PLoS ONE. 2012.

High NRBP1 expression in prostate cancer is linked with poor clinical outcomes and increased cancer cell growth.

Ruiz C; Oeggerli M; Germann M; Gluderer S; Stocker H; Andreozzi M; Thalmann GN; Cecchini MG; Zellweger T; Stürm S; Koivisto PA; Helin HJ; Gelmann EP; Glass AG; Gasser TC; Terracciano LM; Bachmann A; Wyler S; Bubendorf L; Rentsch CA. The Prostate. 2012.

Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response.

Breban R; Bisiaux A; Biot C; Rentsch C; Bousso P; Albert ML. Oncoimmunology. 2012.

Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer

Biot C.; Rentsch C.A.; Gsponer J.R.; Birkhauser F.D.; Jusforgues-Saklani H.; Lemaitre F.; Auriau C.; Bachmann A.; Bousso P.; Demangel C.; Peduto L.; Thalmann G.N.; Albert M.L.. Science Translational Medicine. 2012.

Improved detection of microbial ureteral stent colonisation by sonication.

Bonkat G; Rieken M; Rentsch CA; Wyler S; Feike A; Schäfer J; Gasser T; Trampuz A; Bachmann A; Widmer AF. World Journal of Urology. 2011.

Urethral toxicity vs. cancer control--lessons to be learned from high-dose rate brachytherapy combined with intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.

Ghadjar P; Rentsch CA; Isaak B; Behrensmeier F; Thalmann GN; Aebersold DM. Brachytherapy. 2011.

Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: A joint effort

Cathomas R.; Helbling D.; Stenner F.; Rothermundt C.; Rentsch C.; Shahin O.; Seifert H.-H.; Zaugg K.; Lorch A.; Mayer F.; Beyer J.; De Santis M.; Gillessen S.. Swiss Medical Weekly. 2010.

Interdisciplinary evidence-based recommendations for the follow-up of testicular cancer patients: a joint effort.

Cathomas R; Helbling D; Stenner F; Rothermundt C; Rentsch C; Shahin O; Seifert HH; Zaugg K; Lorch A; Mayer F; Beyer J; De Santis M; Gillessen S. Swiss medical weekly. 2010.

Madm (Mlf1 adapter molecule) cooperates with Bunched A to promote growth in Drosophila.

Gluderer S; Brunner E; Germann M; Jovaisaite V; Li C; Rentsch CA; Hafen E; Stocker H. Journal of biology. 2010.

Prognostic significance of apoptotic cell death in bladder cancer: a tissue microarray study on 179 urothelial carcinomas from cystectomy specimens.

Karamitopoulou E; Rentsch CA; Markwalder R; Vallan C; Thalmann GN; Brunner T. Pathology. 2010.

Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer.

Ghadjar P; Matzinger O; Isaak B; Behrensmeier F; Stroux A; Rentsch CA; Thalmann GN; Aebersold DM. Radiotherapy and Oncology. 2009.

Editorial Comment on: Expression of Aquaporin 1 in Primary Renal Tumors: A Prognostic Indicator of Clear-Cell Renal Cell Carcinoma

Rentsch C.A.; Bachmann A.. European Urology. 2009.

In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue.

Guzmán-Ramírez N; Völler M; Wetterwald A; Germann M; Cross NA; Rentsch CA; Schalken J; Thalmann GN; Cecchini MG. The Prostate. 2009.

Loss of inhibition over master pathways of bone mass regulation results in osteosclerotic bone metastases in prostate cancer.

Rentsch CA; Cecchini MG; Thalmann GN. Swiss Medical Weekly. 2009.

Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy.

Ghadjar P; Keller T; Rentsch CA; Isaak B; Behrensmeier F; Stroux A; Thalmann GN; Aebersold DM. Brachytherapy. 2009.

[Malignant lymphoma of the prostate--diagnosis on the second biopsy].

Vetsch G; Baumann CK; Kläy M; Leupin N; Rentsch C; Mueller-Garamvölgyi E; Bürgi U; Schiemann U. Medizinische Klinik. 2008.

BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.

Buijs JT; Rentsch CA; van der Horst G; van Overveld PG; Wetterwald A; Schwaninger R; Henriquez NV; Ten Dijke P; Borovecki F; Markwalder R; Thalmann GN; Papapoulos SE; Pelger RC; Vukicevic S; Cecchini MG; Löwik CW; van der Pluijm G. American Journal of Pathology. 2007.

Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.

Buijs JT; Henriquez NV; van Overveld PG; van der Horst G; Que I; Schwaninger R; Rentsch C; Ten Dijke P; Cleton-Jansen AM; Driouch K; Lidereau R; Bachelier R; Vukicevic S; Clézardin P; Papapoulos SE; Cecchini MG; Löwik CW; van der Pluijm G. Cancer Research. 2007.

Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.

Schwaninger R; Rentsch CA; Wetterwald A; van der Horst G; van Bezooijen RL; van der Pluijm G; Löwik CW; Ackermann K; Pyerin W; Hamdy FC; Thalmann GN; Cecchini MG. American Journal of Pathology. 2007.

Differential expression of TGFbeta-stimulated clone 22 in normal prostate and prostate cancer.

Rentsch CA; Cecchini MG; Schwaninger R; Germann M; Markwalder R; Heller M; van der Pluijm G; Thalmann GN; Wetterwald A. International Journal of Cancer. 2006.

[Cancer of the prostate: importance of androgen deprivation and radiotherapy].

Rentsch CA; Aebersold DM; Merz V; Studer UE. Revue Medicale Suisse. 2005.

A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.

Shahin O; Thalmann GN; Rentsch C; Mazzucchelli L; Studer UE. Journal of Urology. 2003.

Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.

Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE. Journal of Urology. 2000.